← Leaderboards
Fazlul H. Sarkar
Wayne State University
$12,841,663
Attributed
$12,841,663
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$12,841,663 · 7
By mechanism
R01$12,841,663 · 7
Top collaborators
No co-investigators on record.
Most similar at Wayne State University
Same institution · by research overlap
- Ramzi M. Mohammad$2,204,832
- Gilda G Hillman$346,940
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelNeoplasm MetastasisIn VivoTumorIn VitroBaseMediatingDown-RegulationDesignMalignant NeoplasmsSignal PathwaySignal TransductionCell GrowthCellsAngiogenesisGene TargetingCessation Of LifeMolecularDiagnosisApoptosisPreventionNeoplastic CellNovel StrategiesUnited States
Grant awards (44)
Mechanistic Role of miRNAs and Their Targets in Prostate Cancer Aggressiveness$315,400
R01 · FY2015 · CA · contact PI
Prevention of Tumor Progression by a Novel Approach$315,400
R01 · FY2015 · CA · contact PI
Mechanistic Role of miRNAs and Their Targets in Prostate Cancer Aggressiveness$305,938
R01 · FY2014 · CA · contact PI
Prevention of Tumor Progression by a Novel Approach$305,938
R01 · FY2014 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$286,333
R01 · FY2014 · CA · contact PI
Biological activity of novel rhenium compounds in prostate cancer$41,820
R01 · FY2014 · CA · contact PI
Mechanistic Role of miRNAs and Their Targets in Prostate Cancer Aggressiveness$296,476
R01 · FY2013 · CA · contact PI
Prevention of Tumor Progression by a Novel Approach$296,476
R01 · FY2013 · CA · contact PI
FoxM1: A molecular target in pancreatic cancer$287,582
R01 · FY2013 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$277,478
R01 · FY2013 · CA · contact PI
Mechanistic Role of miRNAs and Their Targets in Prostate Cancer Aggressiveness$315,400
R01 · FY2012 · CA · contact PI
Prevention of Tumor Progression by a Novel Approach$315,400
R01 · FY2012 · CA · contact PI
FoxM1: A molecular target in pancreatic cancer$305,938
R01 · FY2012 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$302,919
R01 · FY2012 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$295,189
R01 · FY2012 · CA · contact PI
Prevention of Tumor Progression by a Novel Approach$315,400
R01 · FY2011 · CA · contact PI
FoxM1: A molecular target in pancreatic cancer$305,938
R01 · FY2011 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$302,919
R01 · FY2011 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$295,189
R01 · FY2011 · CA · contact PI
Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer$260,244
R01 · FY2011 · CA · contact PI
FoxM1: A molecular target in pancreatic cancer$315,400
R01 · FY2010 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$312,288
R01 · FY2010 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$304,318
R01 · FY2010 · CA · contact PI
Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer$268,293
R01 · FY2010 · CA · contact PI
FoxM1: A molecular target in pancreatic cancer$315,400
R01 · FY2009 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$312,288
R01 · FY2009 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$304,000
R01 · FY2009 · CA · contact PI
Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer$268,293
R01 · FY2009 · CA · contact PI
RO1: A novel and targeted approach to inhibit invasion and angiogenesis$312,288
R01 · FY2008 · CA · contact PI
Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer$268,293
R01 · FY2008 · CA · contact PI
Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy$318,565
R01 · FY2007 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$293,510
R01 · FY2007 · CA · contact PI
Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer$268,293
R01 · FY2007 · CA · contact PI
Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy$328,079
R01 · FY2006 · CA · contact PI
Novel Targets of Indoles in Prostate Cancer$302,276
R01 · FY2006 · CA · contact PI
Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy$335,975
R01 · FY2005 · CA
Novel Targets of Indoles in Prostate Cancer$309,550
R01 · FY2005 · CA
Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy$332,571
R01 · FY2004 · CA
Novel Targets of Indoles in Prostate Cancer$309,550
R01 · FY2004 · CA
Molecular Mechanism of Genistein in Prostate Cancer$216,423
R01 · FY2004 · CA
Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy$332,571
R01 · FY2003 · CA
Molecular Mechanism of Genistein in Prostate Cancer$246,887
R01 · FY2003 · CA
Molecular Mechanism of Genistein in Prostate Cancer$257,055
R01 · FY2002 · CA
Molecular Mechanism of Genistein in Prostate Cancer$266,120
R01 · FY2001 · CA